Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Fabrication of environmental sensitive and controllable drug release systems is urgently needed. In this paper, thermosensitive and magnetic response drug release systems were fabricated via layer-by-layer technique using acetylsalicylic acid (AA) intercalated ZnAl-LDH as core, poly (N-isopropylacrylamide) (PNIPAM) and AA micelles as well as small size ZnAl-LDH sheets as building blocks of the shell. By forming anionic micelles, cationic PNIPAM macromolecules were sandwiched in the LDH sheets with cationic charges which provided a novel way of fabrication of drug release systems. The characteristics of the building blocks, the fabrication process and the release behaviors of the as-prepared drug release systems were characterized in detail. Due to the micro-environmental difference of AA in the core and shell of the systems, step-by-step release behaviors were observed. Also the drug release systems showed obvious temperature and magnetic field dependent responsibility. The obtained assembly is a potential drug release system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1088/1361-6528/aaf095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circadian Rhythm Disruption and Sleep Disorders in Alzheimer's Disease: Mechanistic Insights and Therapeutic Potentials.
Neuro Endocrinol Lett
September 2025
Department of Biomedical and Life Sciences, Lancaster University, UK.
Alzheimer's Disease (AD) is the leading cause of dementia worldwide, with significant cognitive and behavioural impairments that devastate individuals and their families. Cohort-level findings, demonstrate the broader population-level implications of Sleep and Circadian Rhythm Disruption (SCRD) in AD and underscore the need for early interventions, emphasizing the importance of timely action. However, the mechanism remains unclear.
View Article and Find Full Text PDFMedications for Opioid Use Disorder in County Jails - Outcomes after Release.
N Engl J Med
September 2025
Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst.
Background: In 2019, seven county correctional facilities (jails) in Massachusetts initiated pilot programs to provide all Food and Drug Administration-approved medications for opioid use disorder (MOUD).
Methods: This observational study used linked state data to examine postrelease MOUD receipt, overdose, death, and reincarceration among persons with probable opioid use disorder (OUD) in carceral settings who did or did not receive MOUD from these programs from September 1, 2019, through December 31, 2020. Log-binomial and proportional-hazards models were adjusted for propensity-score weights and baseline covariates that remained imbalanced after propensity-score weighting.
Discovery of -(thiazol-2-yl) Furanamide Derivatives as Potent Orally Efficacious AR Antagonists with Low BBB Permeability.
J Med Chem
September 2025
State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Resistance-conferring mutations in the androgen receptor (AR) ligand-binding pocket (LBP) compromise the effectiveness of clinically approved orthosteric AR antagonists. Targeting the dimerization interface pocket (DIP) of AR presents a promising therapeutic approach. In this study, we report the design and optimization of -(thiazol-2-yl) furanamide derivatives as novel AR DIP antagonists, among which was the most promising candidate.
View Article and Find Full Text PDFLipidic nanocarriers for the treatment of schizophrenia: progress and prospects of solid lipid nanoparticles and nanostructured lipid carriers.
J Biomater Sci Polym Ed
September 2025
LJ Institute of Pharmacy, Department of Pharmaceutical Technology, LJK University, Ahmedabad, India.
Schizophrenia is a persistent and incapacitating neuropsychiatric condition that presents considerable obstacles regarding pharmacological administration and therapeutic effectiveness. Lipidic nanocarriers, including Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs), have emerged as effective drug delivery vehicles for enhancing the bioavailability, stability, and controlled release of antipsychotic medicines. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have several benefits, such as improved drug loading capacity, less systemic adverse effects, and superior efficacy in traversing the blood-brain barrier compared to conventional formulations.
View Article and Find Full Text PDFElectrically Triggered Fluorescein and Dexamethasone Release from Conducting Polymer Hydrogels.
Tissue Eng Part A
September 2025
Department of Chemical and Materials Engineering, Faculty of Engineering, The University of Auckland, Auckland, New Zealand.
Spatially and temporally controlled drug delivery is an important field to address the limitations of conventional pharmaceutical administration. While many effective controlled drug delivery systems exist, the repertoire of systems that additionally present a beneficial mechanical environment to cells remains scarce. To address this, a comprehensive release study of fluorescein as a model drug, and the corticosteroid dexamethasone, from poly(-isopropylacrylamide)/polypyrrole (pNIPAM/PPy) conducting polymer hydrogels is presented within this study.
View Article and Find Full Text PDF